Merck wins FDA approval of sotatercept for rare lung disease

Merck Fails To Collect Revenue Claimed

Erik S. Lesser

  • The U.S. FDA has approved Merck’s (NYSE:MRK) sotatercept, a treatment or pulmonary arterial hypertension, a rare type of lung disease. It will be marketed under the name Winrevair.
  • Merck shares are up ~5% in after-hours trading.
  • The approval is considered a major victory for patients as Winrevair tackles the source of PAH, rather than currently available therapies which just treat symptoms.
  • The drug will cost $14,000 per vial without insurance, which is given to the vast majority of patients every three weeks, according to The Wall Street Journal. That comes out to roughly $242,000 per year.
  • Merck gained sotatercept in September 2021 through its $11.5B acquisition of Acceleron Pharma.
  • United Therapeutics (UTHR), which markets Tyvaso and Remodulin (treprostinil) for PAH symptoms, is down 7% in after-hours trading.

Harry Byrne

Related post